Loading the records…
Loading the records…
Defense Health Agency · DEFENSE HEALTH AGENCY
Defense Health Agency wants bids for "Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination". The work is in Frederick, MD, USA. Bids are due Nov 20, 2026. In the last 2 years, similar work went to 3 companies, usually for about $2.8M per award. An award is expected between November 2026 and December 2026.
Put together from the facts on this page; the details and sources are below.
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Every notice posted under solicitation HT9427-26-R-E020 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
tifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date). Amendment 0001 � removed alternate point of contact information under �Contract Information� on SAM.gov Amendment 0002 � revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026 Amendment 0003 � revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026 Amendment 0004 - Revised RPP, Attachment A (SOO), Attachment E (Draft Agreement), Attachment H (SOW), and Attachment J (Gov't Responses) in response to vendor questions.
3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), same product/service code (PSC) AN13.
Single-winner award sizes (3): middle half $1.5M to $7.7M, median $2.8M; range $295K to $12.5M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| HEMOGLOBIN OXYGEN THERAPEUTICS LLC | 1 | $12.5M | May 28, 2025 |
| Vascular Solutions LLC | 1 | $2.8M | Oct 27, 2026 |
| UNIVERSITY OF NOTRE DAME DU LAC Notre Dame IN 46556 USA | 1 | $295K | Aug 19, 2026 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.